German Hodgkin Study Group
The Cologne-based group whose HD trials, from BEACOPP to BrECADD in HD21, have set the standard for treating Hodgkin lymphoma for four decades.
Founded in 1978 by Volker Diehl and based at the University Hospital of Cologne, the GHSG has enrolled tens of thousands of patients in sequential HD trials that defined stage-adapted therapy. Its work produced the escalated BEACOPP regimen, showed PET-guided de-escalation is safe (HD16, HD18), and in HD21 showed brentuximab-based BrECADD is less toxic and at least as effective as BEACOPP in advanced disease. The group runs a central review panel for pathology and imaging and long-term survivorship studies of second cancers and cardiac toxicity. It sits within the Department I of Internal Medicine at Cologne.
- HD trial series (HD1-HD21)
- PET-guided treatment adaptation
- HD21 (BrECADD)
- Survivorship and late-effects research
Pages like this
not linked directly; found by shared links- IdeaChemotherapy-free Hodgkin lymphoma: brentuximab + PD-1 in early stage
Shares Brentuximab vedotin, Hodgkin lymphoma, Nivolumab, Antibody-drug conjugate (ADC).
- Key paperECHELON-1: brentuximab vedotin replacing bleomycin in first-line chemotherapy for advanced Hodgkin lymphoma
Shares GHSG HD21, Brentuximab vedotin, Hodgkin lymphoma, Antibody-drug conjugate (ADC).
- TechnologyPET-adapted (response-adapted) therapy
Shares GHSG HD21, FDG PET, Hodgkin lymphoma.
- TrialAHOD2131 (COG / NCTN)
Shares Brentuximab vedotin, Hodgkin lymphoma, Nivolumab.
- TrialKEYNOTE-204
Shares Brentuximab vedotin, Hodgkin lymphoma.
- PersonAlex F. Herrera
Shares Brentuximab vedotin, Hodgkin lymphoma, Nivolumab.
- TrialAETHERA
Shares Brentuximab vedotin, Hodgkin lymphoma.
- InstitutionLYSA – The Lymphoma Study Association
Shares German Lymphoma Alliance, FDG PET, Hodgkin lymphoma.